Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Robert T. Franke"'
Publikováno v:
Psychopharmacology. 235:99-108
Rationale 2-Bromoterguride, a dopamine D2 receptor partial agonist with antagonist properties at serotonin 5-HT2A receptors and α2C-adrenoceptors, meets the prerequisites of a putative atypical antipsychotic drug (APD). We recently showed that 2-bro
Publikováno v:
Psychopharmacology
Rationale Recently, we showed that 2-bromoterguride acted as a dopamine D2 receptor partial agonist, a serotonin 5-HT2A and α2C-adrenergic receptor antagonist, and exhibited antidopaminergic efficacy in amphetamine-induced locomotion (AIL) in rats w
Publikováno v:
Psychopharmacology
Rationale 2-Bromoterguride, a dopamine D2 receptor partial agonist with antagonist properties at serotonin 5-HT2A receptors and α2C-adrenoceptors, meets the prerequisites of a putative atypical antipsychotic drug (APD). We recently showed that 2-bro
Autor:
Florian Jantschak, Dorothee Möller, Robert T. Franke, Harald Hübner, Peter Gmeiner, Heidrun Fink, Jan Brosda, Heinz H. Pertz
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 347(1)
Dopaminergic, serotonergic, and adrenergic receptors are targets for therapeutic actions in schizophrenia. Dopamine D2 receptor partial agonists such as aripiprazole represent a treatment option for patients with this severe disorder. The ineffective